Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Dec 13 2018

Full Issue

Following Intense Scrutiny From Congress, Drugmaker To Offer Significantly Cheaper Version Of Anti-Overdose Medication

Last month a report found that Kaleo had increased the price of Evzio by 600 percent from $575 per unit in July 2014 to $4,100 in January 2017. Lawmakers have criticized the increase that came in the middle of the opioid crisis.

The Hill: Drug Company To Offer Cheaper Opioid Overdose Treatment After Hiking Price 600 Percent 

A drug company is offering a significantly cheaper version of its life-saving opioid overdose treatment after a Senate investigation found that it spiked the price of its drug. A report from the Senate’s Permanent Subcommittee on Investigations last month found that the company, Kaléo, hiked the price of its drug Evzio to $4,100 for two injectors, raising the price by more than 600 percent between 2014 and 2017. (Sullivan, 12/12)

CQ: Drug Manufacturer Announces Cheaper, Generic Opioid Antidote

Kaleo currently sells Evzio, a naloxone auto-injector that uses voice navigation to walk individuals through how to counteract an overdose. The generic will mirror Evzio in terms of design and formulation and is expected to be released in mid-2019. “We have been in dialogues with a broad array with different members of the community — different organizations both in the administration and other members of government,” Omar Khalil, Kaleo’s general manager for addiction and neurology, told CQ. Khalil said this included the Office of the Surgeon General and Sens. Rob Portman, R-Ohio and Thomas R. Carper, D-Del., the top lawmakers on a Senate Homeland Security and Governmental Affairs subcommittee. (Raman, 12/12)

Richmond Times-Dispatch: Kaléo To Create Generic Opioid Overdose Antidote And Cut Prices On Evzio Brand

In addition, a generic version of Evzio should be on the market by midyear 2019 at a list price of $178 per two-dose kit, the company said. Kaléo subsidiary IJ Therapeutics will offer the product. The company’s change to the pricing of the potentially life-saving drug came weeks after Kaléo was the focus of a CBS “60 Minutes” segment in November that reported it “jacked up” the drug’s list price from about $575 to $4,000. The current list price is $4,100, the company confirmed Wednesday. (Smith, 12/12)

Cleveland Plain Dealer: Drug Company Lowers Price Of Overdose Remedy After Sen. Rob Portman Accused It Of Gouging

The company has been working “for some time” with insurers and pharmacy benefit managers to increase access to the drug, said a statement from kaléo President and CEO Spencer Williamson. “With approximately 130 people dying daily from opioid overdoses, we recognize that more needs to be done to improve access for patients,” Williamson’s statement said. (Eaton, 12/12)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF